Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst
Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst POTOMAC, Maryland – August 28, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer’s disease, today announced that Ascendiant Capital Markets has issued an updated […]
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure
Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout POTOMAC, Maryland – August 11, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing treatments for Alzheimer’s disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence (“AI”)-enabled data […]
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign POTOMAC, Maryland – July 29, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced that it is evaluating potential civil remedies following the federal jury […]
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer’s discovery and clinical development
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC
IGC Pharma’s AHA Agentic AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
IGC Pharma’s AHA Agentic AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% in Representative Workflow Patent-pending multi-agent architecture targets fragmented biomedical data and expands toward imaging, omics, and broader health-data applications ahead of planned AAIC 2026 demonstration in London POTOMAC, Maryland – June 23, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage […]
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis Company continuing limited over-enrollment activities to account for attrition and support robust modified intent-to-treat, end-of-treatment, and exploratory analyses POTOMAC, Maryland – June 10, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced that its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer’s dementia has reached the […]
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts POTOMAC, Maryland – June 9, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on the […]
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, Maryland – June, 2, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s […]
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances POTOMAC, MARYLAND – February 17, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that the Canadian Intellectual Property Office (“CIPO”) has issued a Notice of Allowance covering the proprietary composition underlying IGC-AD1, the Company’s Phase 2 clinical stage program for agitation associated with Alzheimer’s disease. With this allowance, patent No. 3,095,729, titled “Method and Composition for Treating CNS Disorders”, IGC has secured composition protection for IGC-AD1 across key North American jurisdictions, reinforcing the long-term […]
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50.”
POTOMAC, MARYLAND, August 27, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced that Ascendiant Capital Markets has issued a coverage report entitled: “Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50.” All reports on IGC Pharma prepared by analysts represent […]
IGC Pharma Reports IGC-M3’s In Vitro Efficacy Against Alzheimer’s – Targeting key Drivers of Disease Progression
– New hope in Alzheimer’s: IGC-M3 targets the disease on four fronts, showing promise in cellular models –
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25”
POTOMAC, MARYLAND, March 12, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets has issued a coverage report entitled Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25 All reports on IGC Pharma […]
IGC Pharma Expands AI Platform with Advanced Diagnostic Model for Alzheimer’s and Dementia Detection
POTOMAC, MARYLAND – March 4, 2025 – IGC Pharma, Inc. ( IGC or the Company ) (NYSE American: IGC) today announced an advancement in its Artificial Intelligence ( AI ) platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer’s disease (AD) and other causes of dementia. With Alzheimer’s […]
Richard Prins FORM 144
IGC Pharma, Inc. IGC on NYSE View File Facebook Twitter LinkedIn Related Posts CEO Update